CORONA Remedies Limited Q3 FY26 results press release summary

Results press release of 2 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹342.42 cr up 15.0% Y-o-Y and PAT ₹55.56 cr up 23.7% Y-o-Y; management aspires to grow revenues 15% and PAT 20% going forward.

Key takeaways

1. Q3 FY26 revenue ₹342.42 cr, up 15.0% Y-o-Y.
2. Q3 FY26 PAT ₹55.56 cr, up 23.7% Y-o-Y.
3. Guidance Aspiration to grow revenues by 15% and PAT by 20%, optimistic of maintaining similar trajectory going forward.
4. Growth driver Strengthening field force, expanding brand portfolio and focus on specialists’ prescriptions.
5. One-time impact Excludes one-time statutory impact of New Labour Code ₹19.10 cr (post tax ₹14.29 cr).

Original filing on BSE

CORONA Remedies Limited Q1 FY27 results

As filed: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
• Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +2.5% in 28 days (Nifty 500: −4.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
• Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
• Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
• Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)